Thomas Kislinger
@kislingerthomas.bsky.social
Senior Scientist at Princess Margaret Cancer Centre, Toronto, Canada 🇨🇦
Clinical proteomics, liquid biopsies and cell surface markers
Clinical proteomics, liquid biopsies and cell surface markers
Reposted by Thomas Kislinger
Interested in surface proteomics for drug discovery?? Come to our @hupo-org.bsky.social Workshop on Sunday, Nov 9 at HUPO in Toronto! Excited to host with Amanda Lorentzain and learn from @berndwollscheid.bsky.social, Susan Klaeger and Thomas Kislinger!
October 23, 2025 at 9:22 PM
Interested in surface proteomics for drug discovery?? Come to our @hupo-org.bsky.social Workshop on Sunday, Nov 9 at HUPO in Toronto! Excited to host with Amanda Lorentzain and learn from @berndwollscheid.bsky.social, Susan Klaeger and Thomas Kislinger!
Reposted by Thomas Kislinger
CNPN2025 will be held on November 8th to kick off HUPO2025!
We have the honor to introduce our keynote speaker and fantastic invited speaker 🥳
@kislingerthomas.bsky.social and @philipplange.bsky.social
For more info about the program: cnpn.ca/cnpn2025/
#precisionmedicine #biomarkerdiscovery
We have the honor to introduce our keynote speaker and fantastic invited speaker 🥳
@kislingerthomas.bsky.social and @philipplange.bsky.social
For more info about the program: cnpn.ca/cnpn2025/
#precisionmedicine #biomarkerdiscovery
October 17, 2025 at 7:39 PM
CNPN2025 will be held on November 8th to kick off HUPO2025!
We have the honor to introduce our keynote speaker and fantastic invited speaker 🥳
@kislingerthomas.bsky.social and @philipplange.bsky.social
For more info about the program: cnpn.ca/cnpn2025/
#precisionmedicine #biomarkerdiscovery
We have the honor to introduce our keynote speaker and fantastic invited speaker 🥳
@kislingerthomas.bsky.social and @philipplange.bsky.social
For more info about the program: cnpn.ca/cnpn2025/
#precisionmedicine #biomarkerdiscovery
Latest preprint from the lab. Great work as always by Meinusha. This is the last chapter for her PhD.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Surface proteomics reveals arginine metabolism as a vulnerability in high grade serous ovarian cancer
The significant lethality of high-grade serous ovarian cancer (HGSC) is driven by the lack of long- term efficacy of current treatments, underscoring the need for developing additional therapeutics. C...
www.biorxiv.org
September 7, 2025 at 12:55 PM
Latest preprint from the lab. Great work as always by Meinusha. This is the last chapter for her PhD.
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Checkout our latest pre-print
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Ancestry-Dependent Immunologic and Prognostic Effects Characterize the Prostate Cancer Urinary Proteome
Urine is an attractive biomarker analyte for non-invasive longitudinal monitoring of health and disease, particularly for diseases of the genitourinary tract, like prostate and bladder cancer. The com...
www.biorxiv.org
August 20, 2025 at 2:08 PM
Checkout our latest pre-print
www.biorxiv.org/content/10.1...
www.biorxiv.org/content/10.1...
Phenotypic screens for SIRPA expression reveal RAB21 as a general regulator of macrophage surface identity: Cell Reports www.cell.com/cell-reports...
Phenotypic screens for SIRPA expression reveal RAB21 as a general regulator of macrophage surface identity
Through CRISPR screening, Granda Farias et al. find results consistent with cis CD47-SIRPA
interactions relying on QPCTL and that RAB21/Rab21 inactivation reduces macrophage
model surface SIRPA/Sirpa ...
www.cell.com
July 1, 2025 at 4:50 PM
Phenotypic screens for SIRPA expression reveal RAB21 as a general regulator of macrophage surface identity: Cell Reports www.cell.com/cell-reports...
checkout our latest paper in @natbiotech.nature.com . We developed a graph-based algorithm that comprehensively generates non-canonical peptides in linear time. www.nature.com/articles/s41...
Identification of non-canonical peptides with moPepGen - Nature Biotechnology
moPepGen enables the detection of peptides across species, proteases and technologies.
www.nature.com
June 16, 2025 at 7:09 PM
checkout our latest paper in @natbiotech.nature.com . We developed a graph-based algorithm that comprehensively generates non-canonical peptides in linear time. www.nature.com/articles/s41...
Reposted by Thomas Kislinger
Identification of non-canonical peptides with moPepGen - @uclahealth.org @uoftmedicine.bsky.social @kislingerthomas.bsky.social go.nature.com/3HYJyyz
Identification of non-canonical peptides with moPepGen - Nature Biotechnology
moPepGen enables the detection of peptides across species, proteases and technologies.
go.nature.com
June 16, 2025 at 2:38 PM
Identification of non-canonical peptides with moPepGen - @uclahealth.org @uoftmedicine.bsky.social @kislingerthomas.bsky.social go.nature.com/3HYJyyz
New collaborative work from PhD student Aastha. Using proteomics for CSF-based biomarker discovery
pubmed.ncbi.nlm.nih.gov/40321620/
pubmed.ncbi.nlm.nih.gov/40321620/
Cerebrospinal fluid protein biomarkers are associated with response to multiagent intraventricular chemotherapy in patients with CNS lymphoma - PubMed
The study identified CSF-based proteomic biomarkers, particularly LCP1, that can classify MAIVC response and indicate tumor burden in CNSL patients.
pubmed.ncbi.nlm.nih.gov
May 5, 2025 at 12:05 PM
New collaborative work from PhD student Aastha. Using proteomics for CSF-based biomarker discovery
pubmed.ncbi.nlm.nih.gov/40321620/
pubmed.ncbi.nlm.nih.gov/40321620/
Last paper for 2024. Nice work by PDF Matt Waas on proteomics of HNSCC tissues to identify novel biomarkers within the N0 population. Great collaboration with Laurie Ailles
and support from many colleagues Princess Margaret Cancer Centre
and support from many colleagues Princess Margaret Cancer Centre
December 30, 2024 at 8:23 PM
Last paper for 2024. Nice work by PDF Matt Waas on proteomics of HNSCC tissues to identify novel biomarkers within the N0 population. Great collaboration with Laurie Ailles
and support from many colleagues Princess Margaret Cancer Centre
and support from many colleagues Princess Margaret Cancer Centre
Reposted by Thomas Kislinger
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers https://www.biorxiv.org/content/10.1101/2024.12.11.627962v1
December 14, 2024 at 2:48 PM
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers https://www.biorxiv.org/content/10.1101/2024.12.11.627962v1
Reposted by Thomas Kislinger
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers https://www.biorxiv.org/content/10.1101/2024.12.11.627962v1
December 14, 2024 at 2:48 PM
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers https://www.biorxiv.org/content/10.1101/2024.12.11.627962v1
Big effort (> 7 years) from a large number of colleagues. Finally on BioRxiv and to be submitted in January
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers
www.biorxiv.org/content/10.1...
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers
www.biorxiv.org/content/10.1...
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers
Cell surface proteins offer significant cancer therapeutic potential attributable to their accessible membrane localization and central role in cellular signaling. Despite this, their promise remains ...
www.biorxiv.org
December 14, 2024 at 4:38 PM
Big effort (> 7 years) from a large number of colleagues. Finally on BioRxiv and to be submitted in January
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers
www.biorxiv.org/content/10.1...
Pan-cancer N-glycoproteomic atlas of patient derived xenografts uncovers FAT2 as a therapeutic target for head and neck cancers
www.biorxiv.org/content/10.1...
Boomerang bowl completed
December 8, 2024 at 8:23 PM
Boomerang bowl completed
A day of skiing at Lake Louise
December 8, 2024 at 8:20 PM
A day of skiing at Lake Louise
Great talk by Meinusha winning a Lake Louise travel award #lakelouise2024
December 6, 2024 at 12:40 AM
Great talk by Meinusha winning a Lake Louise travel award #lakelouise2024
Back at the Lake Louise Tandem Mass Spec conference
December 5, 2024 at 1:32 PM
Back at the Lake Louise Tandem Mass Spec conference